Trial Profile
Reduction of Symptomatic Ventricular Premature Beats With Ranolazine
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 27 Feb 2017
Price :
$35
*
At a glance
- Drugs Ranolazine (Primary)
- Indications Ventricular dysfunction
- Focus Therapeutic Use
- Acronyms RSVP
- 30 Apr 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 05 Dec 2013 New trial record